BioXcel Therapeutics Stock Jumps Over 5% On Completion Of Phase 3 Trial

(RTTNews) - BioXcel Therapeutics, Inc. (BTAI) shares rose 4.21 percent to $1.36 on Friday after the company announced the completion of the last patient last visit in its pivotal Phase 3 SERENITY At-Home clinical trial. The trial evaluates BXCL501 for the treatment of agitation associated with bipolar disorders or schizophrenia in an at-home setting.

The stock is currently trading at $1.39, up $0.08 from the previous close of $1.31 on the Nasdaq. Shares opened at $1.65 and have ranged between $1.34 and $2.07 so far today. Volume has surged to 102.7 million, far above the average daily volume of 344,000. The stock has traded between $1.17 and $16.72 over the past 52 weeks.

The company expects to release topline data from the study later this month. Results will support a planned supplemental New Drug Application for IGALMI to potentially expand its label for outpatient use.